Companies › AiViva BioPharma
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Ophthalmology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AIV007 VEGF inhibitor | – | Phase 2 | Neovascular (Wet) Age-Related Macular Degeneration; Neovascular Age-related Macular Degeneration | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05698329 | AIV007 | Phase 1 | Neovascular Age-related Macular Degeneration | Ophthalmology | Mar 2025 |
| NCT07557121 | AIV007 | Phase 2 | Neovascular (Wet) Age-Related Macular Degeneration | Ophthalmology | Jun 2027 |
No annotated target.
–
EyeBiotech Adverum Biotechnologies EyePoint Pharmaceuticals SpyGlass Pharma Alcon Research
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.